Sign In
Buy ABUS
$4.35
+0.0900 (+2.11%)
At Close: Jun 03, 2026
The Arbutus Biopharma (NASDAQ:ABUS) Share Price Is Up 136% And Shareholders Are Boasting About It
12:59pm, Monday, 17'th Aug 2020
Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right business to buy shares...
ROCE Insights For Arbutus Biopharma
03:27pm, Wednesday, 12'th Aug 2020
Arbutus Biopharma (NASDAQ: ABUS) reported Q2 sales of $1.51 million. Earnings fell to a loss of $13.03 million, resulting in a 0.08% decrease from last quarter. In Q1, Arbutus Biopharma brought in $1.
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
03:30pm, Monday, 10'th Aug 2020
Is (ABUS) Outperforming Other Medical Stocks This Year?
Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates
12:55pm, Friday, 07'th Aug 2020
Arbutus (ABUS) delivered earnings and revenue surprises of -8.70% and -17.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Recap: Arbutus Biopharma Q2 Earnings
11:50am, Friday, 07'th Aug 2020
Shares of Arbutus Biopharma (NASDAQ:ABUS) fell 1% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share rose 45.65% over the past year to ($0.25), which miss
Arbutus Reports Second Quarter 2020 Financial Results and Provides Corporate Update
11:30am, Friday, 07'th Aug 2020
Phase 1a/1b clinical trial for AB-729, a subcutaneously delivered RNAi agent, remains on track with results from additional cohorts expected in the second half of 2020 AB-836, an oral capsid inhibito
Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference
12:00pm, Wednesday, 05'th Aug 2020
WARMINSTER, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chron
Will Arbutus Biopharma (ABUS) Report Negative Earnings Next Week? What You Should Know
04:30pm, Friday, 31'st Jul 2020
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
1 Reason to Sell Moderna Now
10:00pm, Wednesday, 29'th Jul 2020
There are multiple bear arguments floating around as reasons to sell Moderna (NASDAQ: MRNA), one of the drugmakers leading the way to develop a coronavirus vaccine. Moderna lost a petition trying to
Arbutus to Report Second Quarter 2020 Financial Results
12:00pm, Wednesday, 29'th Jul 2020
WARMINSTER, Pa., July 29, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chron
Pfizer/BioNTech COVID-19 Vaccine: A Reality Check
10:47am, Tuesday, 28'th Jul 2020
Pfizer-BioNTech get the go ahead ($1.95 billion contract with the US Government) based on 60 healthy adults receiving first try at formulating the vaccine.
Will Arbutus Biopharma (ABUS) Report Negative Q2 Earnings? What You Should Know
04:31pm, Monday, 27'th Jul 2020
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moderna, Inc.: The Recent Pullback Is No Reason To Accumulate
10:04am, Monday, 27'th Jul 2020
With no safety concerns in the Phase 1 trial, Moderna's COVID-19 vaccine candidate is advancing into late-stage studies.
Moderna's Patent Snub, And Other News: The Good, Bad And Ugly Of Biopharma
09:36am, Monday, 27'th Jul 2020
Moderna has mixed luck with patent snub, but moves ahead with COVID-19 vaccine. Sorrento advances acquisition of SmartPharm.
Moderna says patent ruling not to affect COVID-19 vaccine development
03:52am, Saturday, 25'th Jul 2020
An administrative court run by the U.S. Patent and Trademark Office on Thursday rejected Moderna's arguments to invalidate a U.S. patent owned by Arbutus, sparking worries over its efforts to develop
